相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fasting- Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
Claudio Vernieri et al.
CANCER DISCOVERY (2022)
Triplet Therapy with Palbociclib, Taselisib, and fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual et al.
CANCER DISCOVERY (2021)
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
Giulia Salvadori et al.
CELL METABOLISM (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia
Ishwarya Murali et al.
BLOOD (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2021)
Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative
Kathy Pan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2020)
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Irene Caffa et al.
NATURE (2020)
Fasting mimicking diet as an adjunct toneoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
Stefanie de Groot et al.
NATURE COMMUNICATIONS (2020)
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
Andjelija Zivanovic Bujak et al.
PLOS MEDICINE (2020)
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer
Matthew J. Wongchenko et al.
JCO PRECISION ONCOLOGY (2020)
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Courtney T. van Geelen et al.
BREAST CANCER RESEARCH (2020)
Chromatin interactome mapping at 139 independent breast cancer risk signals
Jonathan Beesley et al.
GENOME BIOLOGY (2020)
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Adi Zundelevich et al.
BREAST CANCER RESEARCH (2020)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Pedram Razavi et al.
NATURE CANCER (2020)
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
S. Hrebien et al.
ANNALS OF ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Dejan Juric et al.
JAMA ONCOLOGY (2019)
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W. Lok et al.
CANCER DISCOVERY (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Ashton C. Berger et al.
CANCER CELL (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Weiyi Toy et al.
CANCER DISCOVERY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
Yuan Yang et al.
ONCOTARGET (2017)
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo et al.
CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Ingrid A. Mayer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
Emily M. Fox et al.
BREAST CANCER RESEARCH (2013)
Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma
Durmus Burgucu et al.
BMC CANCER (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia
E. J. Gallagher et al.
ONCOGENE (2012)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
分享论文
